Clinical trials: Eyes With Glaucoma
Obstructive Sleep Apnea, Hypopnea Syndrome
Retinal Nerve Fiber Layer Thickness Measurements in Patients With Sleep Apnea Syndrome
The purpose of this study was to measure the retinal nerve fiber layer (RNFL) thickness in eyes of Obstructive Sleep Apnea/hypopnea syndrome (OSAHS) using optical coherence tomography (OCT), and assess whether it is decreased.
- Conditions
- Obstructive Sleep Apnea, Hypopnea Syndrome, Glaucoma
- Trial name
- NCT01188291
- Where
- Israel
- Volunteers
- 166 people
- Sponsor
- Carmel Medical Center
Open-Angle Glaucoma, Ocular Hypertension
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT04285580
- Testing
- Bimatoprost SR, LUMIGAN
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- AbbVie
Glaucoma
Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes
This is a randomized, double blind, two-arm, parallel group, active controlled bioequivalence study, at multiple clinical trial sites designed to demonstrate bioequivalence of Brinzolamide 1% ophthalmic suspension (manufactured…
- Trial name
- NCT02512042
- Testing
- Test-Brinzolamide 1% Ophthalmic suspension, Reference-Brinzolamide 1% Ophthalmic suspension
- Where
- 10 sites in United States
- Volunteers
- 973 people
- Sponsor
- Actavis Inc.
Glaucoma, Ocular Hypertension
A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.
- Trial name
- NCT00638742
- Testing
- latanoprost
- Where
- 13 sites in United States, Denmark and 4 more
- Volunteers
- 47 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Ocular Hypertension
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the safety and efficacy of BETOPTIC S and Timolol Gel-forming solution in pediatric patients. Patients will dose with study drug at 8 am and 8 pm daily for twelve weeks.
- Trial name
- NCT00061542
- Testing
- BETOPTIC S (betaxolol HCl), Timolol Gel-forming Solution (TGFS)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Glaucoma, Narrow Angle
Study of a Cilioscleral Interposition Device (CID) SV22 in Patients With Primary Open Angle Glaucoma and Narrow Angle Glaucoma
The purpose of this study is to evaluate the safety and effectiveness of implanting a new version of an interposition supraciliary implant (SV22) as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with…
- Trial name
- SAFARI 3 (NCT05236439)
- Testing
- Interposition supraciliary implant
- Where
- Armenia
- Volunteers
- 57 people
- Sponsor
- Ciliatech
Glaucoma, Open-Angle
Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated
This study will evaluate the safety and efficacy of bimatoprost/timolol fixed combination (GANfort®) versus latanoprost (Xalatan®) in patients with open-angle glaucoma who have never been previously treated and are at high risk…
- Trial name
- NCT01243567
- Testing
- bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution, latanoprost 0.005% ophthalmic solution
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 81 people
- Sponsor
- Allergan
Ocular Hypertension, Open Angle Glaucoma
Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma
The aim of this dose-finding clinical trial is to evaluate the systemic tolerability, local tolerability and intraocular pressure lowering effect of three different doses of SYL040012 in subjects with ocular hypertension or…
- Trial name
- NCT01739244
- Testing
- SYL040012
- Where
- 11 sites in Estonia, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- Sylentis, S.A.
Glaucoma
Study of the Beacon Aqueous Microshunt in Patients With Refractory Glaucoma
This is a prospective, multicenter, single-arm clinical study to evaluate the safety and effectiveness of Beacon Aqueous Microshunt in patients with refractory glaucoma.
- Trial name
- Beacon (NCT04072016)
- Testing
- Beacon Aqueous Microshunt
- Where
- 4 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- MicroOptx
Primary Open Angle Glaucoma
IOP Fluctuations in Primary Open Angle Glaucoma Patients Before and After Deep Sclerectomy With Collagen Implant
Primary open angle glaucoma (POAG) is associated with inadequate drainage of the aqueous humor via the trabecular meshwork towards the systemic circulation. This may lead to an increase in IOP and may damage the optic nerve.
- Trial name
- NCT01561001
- Testing
- SENSIMED Triggerfish®
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Sensimed AG
Ocular Hypertension
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
- Trial name
- NCT00332540
- Testing
- bimatoprost/timolol fixed combination
- Where
- 2 sites in United States, Canada
- Volunteers
- 520 people
- Sponsor
- Allergan
Exfoliation Syndrome, Ocular Hypertension
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Glaucoma is the world's the second leading cause of irreversible blindness. The World Health Organization (WHO) estimated the incidence of blindness due to glaucoma to be 4.4 million people worldwide in 2002.
- Conditions
- Exfoliation Syndrome, Ocular Hypertension, Open Angle Glaucoma
- Trial name
- ROCK (NCT01936389)
- Testing
- AR-12286
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Robert Ritch, MD, LLC.
Open Angle Glaucoma
Determinants of Compliance With Glaucoma Therapy
To determine the association between medical, demographic, socioeconomic, and therapeutic differences on compliance with topical glaucoma therapy using the Travalert device.
- Trial name
- NCT00362622
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Alabama at Birmingham
Open-Angle Glaucoma, Ocular Hypertension
Travoprost 3-Month Safety and Efficacy Study
The purpose of this study was to demonstrate that the intraocular pressure-lowering efficacy of Travoprost 0.003% is equivalent to TRAVATAN® in adult patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01453855
- Testing
- Travoprost ophthalmic solution, 0.003%, Travoprost ophthalmic solution, 0.004%
- Volunteers
- 1,099 people
- Sponsor
- Alcon Research
Glaucoma, Glaucoma, Primary Open Angle
UCP (Ultrasound Cyclo Plasty) in the Treatment of Chinese Patients With Primary Open-angle Glaucoma
Traditional ciliary body photocoagulation treatment uses the photocoagulation of long-wavelength laser to destroy the ciliary body tissue that can produce aqueous humor.
- Trial name
- NCT04321122
- Testing
- ultrasound cyclo plasty
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Uncontrolled Intraocular Pressure
To Assess the Safety and Efficacy of Travacom in Patients With Uncontrolled Intraocular Pressure
This study is a multi-site, unmasked phase IV study. Travacom(R) is a combination topical ocular agent, containing travoprost and timolol, which lower intraocular pressure (IOP) by complementary mechanisms of action.
- Trial name
- NCT01159756
- Testing
- Travacom
- Where
- India
- Volunteers
- 468 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease
The purpose of this study is to compare: the effect of Catioprost® and Travatan Z® on the ocular surface disease (OSD) in subjects with glaucoma or ocular hypertension and ocular surface disease.
- Conditions
- Glaucoma, Ocular Hypertension, Ocular Surface Disease
- Trial name
- NCT01254370
- Testing
- Latanoprost, Travatan Z
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Santen SAS
Glaucoma
Retinal Nerve Fiber Layer Thickness Measurement on Parapapillary Atrophy With the Cirrus High-Definition (HD) Optical Coherence Tomography (OCT)
Retinal nerve fiber layer (RNFL) thickness measurement on the parapapillary atrophy is incorrect. Because a new spectral domain OCT, the Cirrus HD OCT, uses a movable circle to analyze the RNFL thickness, we may suggest a new…
- Trial name
- NCT00742196
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Glaucoma, Age-related Macular Degeneration
Evaluation of New Head-mounted Visual Aids Among Patients With Low Vision
Glaucoma, age-related macular degeneration (AMD), retinitis pigmentosa, RP, diabetic retinopathy (DR) are the most common blinding eye diseases in the world.
- Conditions
- Glaucoma, Age-related Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy
- Trial name
- NCT06076720
- Testing
- New head-mounted visual aids
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Open Angle Glaucoma, Ocular Hypertension
A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension
This is a Phase I/II stage to investigate the safety, tolerability, and ocular hypotensive efficacy of TO-O-1001 in healthy volunteers and patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT05456724
- Testing
- TO-O-1001
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Theratocular Biotek Co.